Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture its generic version of Paliperidone extended-release tablets, used to treat ...
Two new studies that compared antipsychotics seek to fill that gap. The first, which Hamina led, measured the efficacy of ...
Teva already presented in June 2024 data informing clinical strategies for switching patients to UZEDY from a once-monthly intramuscular injection of Invega Sustenna ® (paliperidone palmitate) ...
INVEGA HAFYERA contains the active ingredient paliperidone palmitate. INVEGA HAFYERA is used to treat schizophrenia in adults (18 years of age and older). For more information, see Section 1.
Ahmedabad: Zydus Lifesciences Limited has announced that it has received in principle acceptability from World Health ...
Background: To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone immediate-release using propensity score methodology. Methods: Six double-blind ...
TCS reported a net profit of Rs 11,909 crore for Q2FY25, up 5 per cent year-on-year but down 1.08 per cent sequentially: stocks to watch ...
Paliperidone (as palmitate) 273mg, 410mg, 546mg, 819mg; ext-rel susp for IM inj. Schizophrenia after adequately treated with Invega Sustenna (1-month paliperidone palmitate ext-rel inj susp ...
Nov. 4, 2024 — The temperature of elementary particles has been observed in the radioactive glow following the collision of two neutron stars and the birth of a black hole. This has, for the ...
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.
Johnson & Johnson (NYSE: JNJ) announced today that 23 abstracts featuring new real-world and clinical trial data from across its neuropsychiatry portfolio and pipeline will be presented at the annual ...
United Statescategory Michigan city of Warren in focus amid worries about delayed election results November 2, 2024 United Statescategory Harris and Trump locked in tight race in swing states, NYT ...